

Lomustine SDS/MSDS (Safety Data Sheet)

1. PRODUCT AND COMPANY IDENTIFICATION

Product identifier

- * Product Name: Lomustine
- * Catalog Number: S1840
- * CAS Number: 13010-47-4
- * IUPAC Name: N-(2-chloroethyl)-N'-cyclohexyl-N-nitroso-urea

Relevant identified uses and uses advised against

- * Identified uses: For research and development use only; laboratory chemicals; manufacture of substances.
- * Uses advised against: Not for pharmaceutical, household, or other unapproved uses.

Details of the supplier

- * Company: Selleck Chemicals
- * TollFree: +1 877 796-6397
- * Tel: +1 832 582-8158
- * Fax: +1 832 582-8590

Emergency telephone number

- * Emergency phone #: +1 832 582-8158

2. HAZARDS IDENTIFICATION

2.1 GHS classification in accordance with 29 CFR 1910 (OSHA HCS):

- Flammable solids: Category 1. H228
- Not classified. H242
- Acute toxicity (oral): Category 3. H301
- Germ cell mutagenicity: Category 1. H340
- Carcinogenicity: Category 1. H350
- Reproductive toxicity: Category 1. H360
- Specific target organ toxicity (single exposure): Category 1. H370
- Specific target organ toxicity (single exposure): Category 2. H371
- Specific target organ toxicity (repeated exposure): Category 1. H372
- Specific target organ toxicity (repeated exposure): Category 2. H373

2.2 GHS Label elements, including precautionary statements

Hazard Pictogram(s)



Signal Word

Danger

Hazard statement(s)	<p>H228: Flammable solid</p> <p>H242: Heating may cause a fire</p> <p>H301: Toxic if swallowed</p> <p>H340: May cause genetic defects</p> <p>H350: May cause cancer</p> <p>H360: May damage fertility or the unborn child</p> <p>H370: Causes damage to organs</p> <p>H371: May cause damage to organs</p> <p>H372: Causes damage to organs through prolonged or repeated exposure</p> <p>H373: May causes damage to organs through prolonged or repeated exposure</p>
Precautionary statement(s)	None.
Prevention	<p>P203: Obtain, read and follow all safety instructions before use.</p> <p>P210: Keep away from heat, hot surface, sparks, open flames and other ignition sources. No smoking.</p> <p>P234: Keep only in original container.</p> <p>P235: Keep cool.</p> <p>P240: Ground/bond container and receiving equipment.</p> <p>P241: Use explosion-proof electrical/ventilating/lighting equipment.</p> <p>P260: Do not breathe dust/fume/gas/mist/vapors/spray.</p> <p>P264: Wash hands thoroughly after handling.</p> <p>P270: Do not eat, drink or smoke when using this product.</p> <p>P280: Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.</p>
Response	<p>P301+P316: IF SWALLOWED: Get emergency medical help immediately.</p> <p>P308+P316: IF exposed or concerned: Get emergency medical help immediately.</p> <p>P318: if exposed or concerned, get medical advice.</p> <p>P319: Get medical help if you feel unwell.</p> <p>P321: Specific treatment (see information on this label and safety datasheet)).</p> <p>P330: Rinse mouth.</p> <p>P370+P378: In case of fire: Use water spray, dry chemical, carbon dioxide, or appropriate foam to extinguish.</p>
Storage	<p>P403: Store in a well-ventilated place.</p> <p>P405: Store locked up.</p> <p>P410: Protect from sunlight.</p> <p>P411: Store at appropriate temperatures(see Section 7).</p> <p>P420: Store separately.</p>
Disposal	P501: P501 Dispose of contents/ container to an approved waste disposal plant.

2.3 Other hazards

None.

3. COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Product name: Lomustine

CAS Number: 13010-47-4

PubChem CID: 3950

Molecular formula: C₉H₁₆ClN₃O₂

Molecular weight: 233.69 g/mol

IUPAC name: 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea

3.2 Mixtures

Not applicable (pure substance).

4. FIRST-AID MEASURES

4.1 Description of first aid measures

Inhalation: Move to fresh air. Keep at rest in a position comfortable for breathing. Seek medical attention if symptoms persist.

Skin contact: Wash with plenty of soap and water. Remove contaminated clothing. Seek medical attention if irritation develops.

Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention.

Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Seek medical attention.

4.2 Most important symptoms and effects, both acute and delayed

See Section 11 (Toxicological Information).

4.3 Indication of any immediate medical attention and special treatment needed

Treat symptomatically. Contact a poison control center or physician for severe exposure.

5. FIRE-FIGHTING MEASURES

5.1 Extinguishing media

Suitable: Dry chemical, carbon dioxide (CO₂), alcohol-resistant foam, water spray.

Unsuitable: High-pressure water jet (may spread fire).

5.2 Specific hazards arising from the substance or mixture

Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Special protective equipment for fire-fighters: Wear self contained breathing apparatus for fire fighting if necessary.

5.3 Advice for firefighters

Wear self-contained breathing apparatus (SCBA) and full protective clothing.

Fight fire from upwind. Cool containers with water spray until fire is extinguished.

6. ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

Wear appropriate personal protective equipment (see Section 8).

Avoid breathing dust/vapor. Ensure adequate ventilation.

Evacuate personnel to safe areas. Keep people away from and upwind of spill.

WARNING: Highly toxic — only trained personnel should handle spills.

6.2 Environmental precautions

Prevent product from entering drains, waterways, or soil.

Contain spill with inert absorbent material.

6.3 Methods and materials for containment and cleaning up

Personal precautions: Use personal protective equipment. Avoid dust formation. Avoid breathing dust. Ensure adequate ventilation. Evacuate personnel to safe areas.

Environmental precautions: Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

Methods for cleaning up: Pick up and arrange disposal without creating dust. Keep in suitable, closed containers for disposal.

/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Spill kits containing all materials needed to clean up spills of hazardous drugs should be assembled or purchased. These kits should be readily available in all areas where hazardous drugs are routinely handled. If hazardous drugs are being prepared or administered in a nonroutine area (home setting or unusual patient-care area), a spill kit should be obtained by the drug handler. The kit should include two pairs of disposable gloves (one outer pair of utility gloves and one inner latex pair); low-permeability, disposable protective garments (coveralls or gown and shoe covers); safety glasses or splash goggles; respirator; absorbent, plastic-backed sheets or spill pads; disposable toweling; at least 2 sealable thick plastic hazardous waste disposal bags (prelabeled with an appropriate warning label); a disposable scoop for collecting glass fragments; and a puncture-resistant container for glass fragments. All individuals who routinely handle hazardous drugs must be trained in proper spill management and cleanup procedures. Spills and breakages must be cleaned up immediately according to the following procedures. If the spill is not located in a confined space, the spill area should be identified and other people should be prevented from approaching and spreading the contamination. Wearing protective apparel from the spill kit, workers should remove any broken glass fragments and place them in the puncture-resistant container. Liquids should be absorbed with a spill pad; powder should be removed with damp disposable gauze pads or soft toweling. The hazardous material should be completely removed and the area rinsed with water and then cleaned with detergent. The spill cleanup should proceed progressively from areas of lesser to greater contamination. The detergent should be thoroughly rinsed and removed. All contaminated materials should be placed in the disposal bags provided and sealed and transported to a designated containment receptacle. Spills occurring in the biohazard cabinet should be cleaned up immediately; a spill kit should be used if the volume exceeds 150 ml or the contents of one drug vial or ampule. If there is broken glass, utility gloves should be worn to remove it and place it in the puncture-resistant container located in the biohazard cabinet. The biological safety cabinet, including the drain spillage trough, should be thoroughly cleaned. If the spill is not easily and thoroughly contained, the biological safety cabinet should be decontaminated after cleanup. If the spill contaminates the high efficiency particulate air filter, use of the biological safety cabinet should be suspended until the cabinet has been decontaminated and the high efficiency particulate air filter replaced. **/Antineoplastic agents/**

For more Cleanup Methods (Complete) data for LOMUSTINE (6 total), please visit the HSDB record page.

SRP: Criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

Dissolve or mix the material with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber. Observe all federal, state, and local environmental regulations. Contact a licensed professional waste disposal service to dispose of this material.

/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ All contaminated disposables should be contained in sealable bags for transfer to larger waste containers. **/Antineoplastic agents/**

/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ All bottles must be discarded as contaminated waste after decontamination of the biohazard cabinet. All protective apparel (gown, gloves, goggles, and respirator) should be discarded as contaminated waste. **/Antineoplastic agents/**

For more Disposal Methods (Complete) data for LOMUSTINE (14 total), please visit the HSDB record page.

In case of skin contact: Wash off with soap and plenty of water. Consult a physician.

In case of eye contact: Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Hygiene measures: Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling the product.

/PRECAUTIONS FOR ANTINEOPLASTIC AGENTS:/ Accidental contamination of the health-care environment, resulting in exposure of personnel, patients, visitors, and family members to hazardous substances, is prevented by maintaining the physical integrity and security of packages of hazardous drugs. 1. Access to all areas where hazardous drugs are stored is limited to specified authorized staff. 2. A method should be present for identifying to personnel those drugs that require special precautions (eg, cytotoxics). One way to accomplish this is to apply appropriate warning labels to all hazardous drug containers, shelves, and bins where the drug products are stored. ... 3. A method of identifying, for patients and family members, those drugs that require special precautions in the home should be in place. This may be accomplished in the health-care setting, by providing specific labeling for discharge medications, along with written instructions. 4. Methods for identifying shipping cartons of hazardous drugs should be required from manufacturers and distributors of these drugs. 5. Written procedures for handling damaged packages of hazardous drugs should be maintained. Personnel involved in shipping and receiving hazardous drugs should be trained in these procedures, including the proper use of protective garments and equipment. Damaged shipping cartons of hazardous drugs should be received and opened in an isolated area (eg, in a laboratory fume hood, if available, not in a vertical laminar airflow biological safety cabinet used for preparing sterile products). /Antineoplastic agents/

For more Preventive Measures (Complete) data for LOMUSTINE (32 total), please visit the HSDB record page.

7. HANDLING AND STORAGE

7.1 Precautions for safe handling

Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: -20 °C. Light sensitive.

Commercially available lomustine capsules should be stored in well-closed containers at a temperature less than 40 °C.

The bulk drug should be stored in a deep freeze and protected from moisture.

PRECAUTIONS FOR "CARCINOGENS": Storage site should be as close as practical to lab in which carcinogens are to be used, so that only small quantities required for ... expt need to be carried. Carcinogens should be kept in only one section of cupboard, an explosion-proof refrigerator or freezer (depending on chemico-physical properties ...) that bears appropriate label. An inventory ... should be kept, showing quantity of carcinogen & date it was acquired ... Facilities for dispensing ... should be contiguous to storage area. /Chemical Carcinogens/

Keep away from heat, sparks, and open flames. Use explosion-proof equipment.

7.2 Conditions for safe storage, including any incompatibilities

Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Recommended storage temperature: -20 °C. Light sensitive.

Commercially available lomustine capsules should be stored in well-closed containers at a temperature less than 40 °C.

The bulk drug should be stored in a deep freeze and protected from moisture.

PRECAUTIONS FOR "CARCINOGENS": Storage site should be as close as practical to lab in which carcinogens are to be used, so that only small quantities required for ... expt need to be carried. Carcinogens should be kept in only one section of cupboard, an explosion-proof refrigerator or freezer (depending on chemico-physical properties ...) that bears appropriate label. An inventory ... should be kept, showing quantity of carcinogen & date it was acquired ... Facilities for dispensing ... should be contiguous to storage area. /Chemical Carcinogens/

Store away from incompatible materials (see Section 10).

[Note: Specific storage temperature not available in public databases. Refer to supplier Certificate of Analysis (COA) for exact storage conditions.]

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Exposure controls

8.1.1 Occupational exposure limits (OEL)

OSHA PEL: Not established.

ACGIH TLV: Not established.

NIOSH REL: Not established.

No occupational exposure limit values are established for this substance.

Use the lowest feasible exposure level (ALARA principle).

8.1.2 Appropriate engineering controls

Use in a well-ventilated area. Chemical fume hood recommended for powder handling.

8.2 Individual protection measures

8.2.1 Eye/face protection

Wear safety glasses with side shields.

8.2.2 Skin protection

Wear protective gloves. Recommended material: Nitrile rubber.

Wear suitable protective clothing (lab coat).

8.2.3 Respiratory protection

Respiratory protection usually not required under normal use with adequate ventilation.

Use N95 respirator for large-scale powder handling.

8.2.4 Thermal hazards

Not applicable.

9. PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

- a) Appearance: Solid
- b) Odor: No data available
- c) Odor threshold: No data available
- d) pH: No data available
- e) Melting point/freezing point: 88-90 °C
- f) Initial boiling point and boiling range: No data available
- g) Flash point: No data available
- h) Evaporation rate: No data available
- i) Flammability (solid, gas): No data available
- j) Upper/lower flammability or explosive limits: No data available
- k) Vapor pressure: No data available
- l) Vapor density: No data available
- m) Relative density: No data available
- n) Water solubility: Soluble in ethanol

- o) Partition coefficient: n-octanol/water: Log P (n-octanol/water): 2.8
- p) Auto-ignition temperature: No data available
- q) Decomposition temperature: No data available
- r) Viscosity: No data available
- s) Explosive properties: No data available
- t) Oxidizing properties: No data available

9.2 Other information

Topological Polar Surface Area (TPSA): 61.8 Å²
Complexity: 219

10. STABILITY AND REACTIVITY

10.1 Reactivity

No specific reactivity hazards identified under normal handling conditions.

10.2 Chemical stability

Stable under recommended storage conditions.

10.3 Possibility of hazardous reactions

No hazardous reactions under normal conditions.

10.4 Conditions to avoid

Avoid heat, sparks, open flames, direct sunlight, and moisture.
Avoid strong oxidizing agents, strong acids, and strong bases.

10.5 Incompatible materials

Materials to avoid: Strong oxidizing agents, strong bases.

10.6 Hazardous decomposition products

Thermal decomposition may produce: Carbon monoxide (CO), Carbon dioxide (CO₂), Nitrogen oxides (NO_x), Hydrogen chloride (HCl).
See also Section 5 (Fire-fighting measures) for combustion products.

11. TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects

Acute toxicity:

No acute toxicity data available.

Skin corrosion/irritation:

No data available.

Serious eye damage/eye irritation:

No data available.

Respiratory or skin sensitization:

No data available.

Germ cell mutagenicity:

May cause genetic defects (H340).

Carcinogenicity:

May cause cancer (H350).

Reproductive toxicity:

May damage fertility or the unborn child (H360).

Specific target organ toxicity (single exposure):

H370, H371, H372, H373

Specific target organ toxicity (repeated exposure):

No data available.

Aspiration hazard:

No data available.

11.2 Additional information

Carcinogen classification:

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine)

Group 2A: Probably carcinogenic to humans

Volume 26: (1981) Some Antineoplastic and Immunosuppressive Agents

Volume Sup 7: Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42, 1987; 440 pages; ISBN 92-832-1411-0 (out of print)

1987

1987

NB Overall evaluation upgraded to Group 2A with supporting evidence from other relevant data

2A, probably carcinogenic to humans. (L135)

Exposure routes:

Well and rapidly absorbed from the gastrointestinal tract.

Data source: Hazardous Substances Data Bank (HSDB) via PubChem.

12. ECOLOGICAL INFORMATION

12.1 Toxicity

Lomustine's production and use as an antineoplastic may result in its release to the environment through various waste streams. If released to air, an estimated vapor pressure of 2.6×10^{-5} mm Hg at 25 °C indicates lomustine will exist in both the vapor and particulate phases in the atmosphere. Vapor-phase lomustine will be degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals; the half-life for this reaction in air is estimated to be 18 hours. Particulate-phase lomustine will be removed from the atmosphere by wet or dry deposition. Lomustine does not contain chromophores that absorb at wavelengths >290 nm and therefore is not expected to be susceptible to direct photolysis by sunlight. If released to soil, lomustine is expected to have moderate mobility based upon an estimated Koc of 200. However, by analogy to N-nitroso-N-ethylurea which exhibited a hydrolysis half-life of 47 minutes at pH 9, adsorption may be precluded by hydrolysis. Volatilization from moist soil surfaces is not expected to be an important fate process based upon an estimated Henry's Law constant of 1.8×10^{-10} atm-cu m/mole. Biodegradation data were not available. If released into water, lomustine is expected to adsorb to suspended solids and sediment based upon the estimated Koc. Volatilization from water surfaces is not expected to be an important fate process based upon this compound's estimated Henry's Law constant. An estimated BCF of 34 suggests the potential for biocon

12.2 Persistence and degradability

No data available.

12.3 Bioaccumulative potential

Log P (n-octanol/water): 2.8

Low potential for bioaccumulation (Log P < 3).

12.4 Mobility in soil

No data available.

12.5 Results of PBT and vPvB assessment

PBT/vPvB assessment not available.

12.6 Other adverse effects

No other adverse ecological effects identified.

13. DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Waste Treatment Methods: Waste material must be disposed of in accordance with national and local regulations. Leave chemicals in original containers and do not mix with other waste. Handle uncleaned containers in the same manner as the product itself.

14. TRANSPORT INFORMATION

14.1 UN number

UN 2811

14.2 UN proper shipping name

Toxic solid, organic, NOS (Lomustine)[Sigma-Aldrich; Safety Data Sheet for Lomustine (Product Number: L5918) Version 3.1 (June 19, 2009). Available from, as of November 20, 2009: <http://www.sigmaaldrich.com>]

14.3 Transport hazard class(es)

Consult official transport regulations (DOT/IATA/IMDG) for hazard classification.

14.4 Packing group

Consult official transport regulations (DOT/IATA/IMDG) for packing group assignment.

14.5 Environmental hazards

Marine pollutant: No (not classified as environmentally hazardous per GHS).

14.6 Special precautions for user

Transport in original packaging. Ensure containers are tightly sealed.

For bulk or commercial quantities, consult applicable transport regulations (DOT, IATA, IMDG).

14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable.

15. REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

US EPA / TSCA: Not available in public databases.

EU ECHA / REACH: Not available in public databases.

SARA 302 Components:

No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 Components:

This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

SARA 311/312 Hazards:

Acute (short-term) health hazard

Chronic (long-term) health hazard

Fire hazard

Reactive hazard

Massachusetts Right To Know Components:

This material contains components subject to the Massachusetts Right to Know Act. See Section 2 for hazard classification.

Pennsylvania Right To Know Components:

This material contains components subject to the Pennsylvania Right to Know Act. See Section 2 for hazard classification.

New Jersey Right To Know Components:

This material contains components subject to the New Jersey Right to Know Act. See Section 2 for hazard classification.

California Prop. 65 Components:

This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.

Other regulatory listings:

- California Safe Cosmetics Program (CSCP) Reportable Ingredient: Hazard Traits - Carcinogenicity; Developmental Toxicity Authoritative List - IARC Carcinogens - 2A; NTP RoC - reasonable; Prop 65 Report - regardless of intended function of ingredient in the product
- FDA Requirements: The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl lomustine, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act.

15.2 Chemical safety assessment

A chemical safety assessment has not been carried out for this substance.

For research-use-only compounds, no CSA is required under REACH Annex I.

16. OTHER INFORMATION

Revision Date: 2026/09/08

Further Information: The information provided is believed to be correct but is not exhaustive and should be used only as a guideline based on current knowledge. It does not represent a guarantee of the properties of the product. Selleck Chemicals Corporation and its Affiliates shall not be held liable for any damage resulting from handling or contact with the product.